Drug Trial Radar · NCT02770807
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Mar 2, 2017
Primary completion
May 13, 2021
Study completion May 13, 2021
Sponsor
- Lead sponsor
- Quince Therapeutics S.p.A.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objectives: The objective of study was to evaluate the safety and the efficacy of EryDex (Dexamethasone sodium phosphate encapsulated in autologous erythrocytes, using the EryDex System - EDS) at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on Neurological Symptoms in Patients With Ataxia Telangiectasia. Initial Double-Blind Treatment Period (0 to 6 Months) Primary Efficacy Objective: • Evaluate the effect of EryDex at two dose levels (low dose and high dose DSP/infusion), compared to placebo, on central nervous system (CNS) symptoms measured by the change in the Modified International Cooperative Ataxia Rating Scale (mICARS) from baseline to Month 6 (Visit 9) in patients with ataxia telangiectasia (A-T). Secondary Efficacy Objectives: * Evaluate the effect of EryDex, compared to placebo, on the Clinical Global Impression of Change (CGI-C) in patients with A-T from baseline to Month 6 (Visit 9). * Evaluate the effect of EryDex, compared to placebo, on measures of Clinical Global Impression of Severity (CGI-S; structured) in patients with A-T from baseline to Month 6 (Visit 9) * Evaluate the effect of EryDex, compared to placebo, on measures of Adaptive behavior measures in patients with A-T by the Vineland Adaptive Behavior Scales (VABS) from baseline to Month 6 (Visit 9). Safety Objectives: • Evaluate the safety and tolerability of two non-overlapping doses of EryDex, compared to placebo, in patients with A-T over the 12-month double-blind study duration. Extension Treatment Period (6-12 Months): Primary Objective: • Evaluate the efficacy of EryDex at two dose levels (low dose and high dose DSP/infusion) compared to placebo, in treating CNS symptoms in A-T patients during longer-term treatment (up to 12 months), as measured by the mICARS. Secondary Objectives: * Evaluate the longer-term (up to 12 months) safety and tolerability of EryDex in A-T patients. * Compare the effects of EryDex on the CGI-C and CGI-S (structured), VABS, and QoL using the EQ-5D-5L scale.
Conditions
- Nervous System Disease
- Genetic Syndrome
Interventions
EryDex Low dose DSPDrug
EDS-EP dose range of \~5-10 mg DSP/infusion
EryDex High dose DSPDrug
EDS-EP dose range of \~14-22 mg DSP/infusion
Pooled PlaceboDrug
EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Modified International Cooperative Ataxia Rating Scale (mICARS)Time frame: to Month 6 (Visit 9)
Locations
22 sites in 12 countries. Site status is shown where the registry gives one.
UCLA-Ataxia Center and HD Center of Exellence
Los Angeles, California
The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital
Baltimore, Maryland
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
UT Health
Houston, Texas
Royal Children's Hospital
Melbourne, Victoria, Australia
Laboratoriumgeneeskunde
Leuven, Belgium
Klinik für Kinder- und Jugendmedizin Pädiatrische Allergologie, Pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany
All India Institute of Medical Sciences
New Delhi, India
National Institute of Mental Health and Neurosciences
Bangalore, Karnataka, India
Amrita Institute of Medical Sciences and Research Centre
Kochi, Kerala, India
Jaslok Hospital and Research Centre
Mumbai, Maharashtra, India
PD Hinduja National Hospital and Medical Research
Mahīm, Mumbai, India
Vijaya Health Centre, Department of Neurology
Chennai, Tamil Nadu, India
Nizam's Institute of Medical Sciences
Hyderabad, Telangana, India
Sheba Medical Center
Tel HaShomer, Israel
U.O. Neurologia e Psichiatria dell'Infanzia e dell' Adolescenza. ASST Spedali Civili, Piazzale Spedali Civili, 1
Brescia, Italy
Dipartimento di Pediatria e Neuropsichiatria Infantile, Università Sapienza di Roma, Azienda Policlinico Universitario Umberto I
Rome, Italy
Norwegian National Unit for Newborn Screening, Division of Pediatric and Adolescent Medicine, Oslo University Hospital
Oslo, Norway
Department of Clinical Immunology The Children's Memorial Health Institute
Warsaw, Poland
Hospital Universitario La Paz.
Madrid, Spain
El Razi Hospital
Manouba, Tunisia
Nottingham University Hospitals NHS Trust - Queen's Medical Centre
Nottingham, Nottinghamshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.